000303026 001__ 303026
000303026 005__ 20250722114136.0
000303026 0247_ $$2doi$$a10.21037/jgo-2025-392
000303026 0247_ $$2pmid$$apmid:40672076
000303026 0247_ $$2pmc$$apmc:PMC12261016
000303026 0247_ $$2ISSN$$a2078-6891
000303026 0247_ $$2ISSN$$a2219-679X
000303026 037__ $$aDKFZ-2025-01473
000303026 041__ $$aEnglish
000303026 082__ $$a610
000303026 1001_ $$aHuang, Dayin$$b0
000303026 245__ $$aCDK12 inhibition enhances oxaliplatin efficacy in gastric cancer by suppressing the MAPK signaling pathway.
000303026 260__ $$aHong Kong$$bPioneer Bioscience Publ.$$c2025
000303026 3367_ $$2DRIVER$$aarticle
000303026 3367_ $$2DataCite$$aOutput Types/Journal article
000303026 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1753098778_5172
000303026 3367_ $$2BibTeX$$aARTICLE
000303026 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303026 3367_ $$00$$2EndNote$$aJournal Article
000303026 520__ $$aGastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Oxaliplatin (OXA) based therapy plus/minus targeted therapy and immune check point inhibitors is the standard first-line treatment for advanced GC; however, its clinical efficacy is often hindered by the development of drug resistance. Cyclin-dependent kinase 12 (CDK12), a transcriptional regulator linked to DNA repair, plays a crucial role in transcription, cancer progression as well as drug resistance, where its exact role is unclear. In this study, we will investigate the role of CDK12 in GC progression and its potential as a therapeutic target specifically to enhance the efficacy of OXA.CDK12 expression in GC tissues was analyzed by quantitative polymerase chain reaction (qPCR) and tissue microarrays (TMAs). A Kaplan-Meier survival analysis was conducted to assess the relationship between CDK12 levels and clinical outcomes. The effect of the CDK12 inhibitor combined with OXA was evaluated through in vivo and in vitro models. RNA-sequencing and western blots were used to investigate the molecular mechanisms of CDK12 inhibitor sensitizing OXA.CDK12 exhibited significant amplification frequency in GC. The Mendelian-randomization analysis revealed a positive causal association between elevated CDK12 expression and an increased risk of GC. Additionally, CDK12 was significantly overexpressed in GC tissues compared with adjacent normal tissues, and its high expression was significantly associated with a worse prognosis. The functional assays revealed that combining the CDK12 inhibitor THZ531 with OXA synergistically suppressed GC cell proliferation, induced apoptosis, and reduced colony formation in vitro, while substantially inhibiting tumor growth in xenograft models. Mechanistically, CDK12 inhibition disrupted MAPK signaling, leading to enhanced OXA-induced DNA damage and potentiated anti-tumor effects.Our findings suggest that CDK12 inhibition may represent a promising strategy for overcoming OXA resistance and improving GC treatment outcomes.
000303026 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000303026 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303026 650_7 $$2Other$$aGastric cancer (GC)
000303026 650_7 $$2Other$$acell cycle
000303026 650_7 $$2Other$$acombination therapy
000303026 650_7 $$2Other$$acyclin-dependent kinase 12 (CDK12)
000303026 650_7 $$2Other$$aoxaliplatin (OXA)
000303026 7001_ $$aXiong, Zhizhong$$b1
000303026 7001_ $$aZhong, Bin$$b2
000303026 7001_ $$aLi, Xianwen$$b3
000303026 7001_ $$aMohamed, Saddam Ahmed$$b4
000303026 7001_ $$aSun, Jiachen$$b5
000303026 7001_ $$aXu, Haoyang$$b6
000303026 7001_ $$aGuo, Jianping$$b7
000303026 7001_ $$aDeng, Zijian$$b8
000303026 7001_ $$0P:(DE-He78)a92f91afa83da73641a4f3abec1d3c6d$$aLi, Xianzhe$$b9$$udkfz
000303026 7001_ $$aAlmhanna, Khaldoun$$b10
000303026 7001_ $$aChen, Yonghe$$b11
000303026 7001_ $$aLian, Lei$$b12
000303026 773__ $$0PERI:(DE-600)2594644-4$$a10.21037/jgo-2025-392$$gVol. 16, no. 3, p. 823 - 839$$n3$$p823 - 839$$tJournal of gastrointestinal oncology$$v16$$x2078-6891$$y2025
000303026 909CO $$ooai:inrepo02.dkfz.de:303026$$pVDB
000303026 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a92f91afa83da73641a4f3abec1d3c6d$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000303026 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000303026 9141_ $$y2025
000303026 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ GASTROINTEST ONCOL : 2022$$d2024-12-18
000303026 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000303026 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000303026 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000303026 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000303026 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-18
000303026 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000303026 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000303026 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000303026 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000303026 980__ $$ajournal
000303026 980__ $$aVDB
000303026 980__ $$aI:(DE-He78)C070-20160331
000303026 980__ $$aUNRESTRICTED